The Perfect Enemy | Year: 2022 | Page 480
September 26, 2025

Year: 2022

Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19

EQS-News: Atriva Therapeutics GmbH / Key word(s): Study results/Research UpdateAtriva Therapeutics announces Topline Results from the Proof of Concept (POC)...